Promising Pharmaceutical Stocks To Research - April 29th

Key Points

• MarketBeat's screener flags five pharmaceutical stocks to watch today: LLY, KALV, ABBV, REGN, and TEVA, which had the highest dollar trading volume among pharma names in recent days.
• Pharmaceutical stocks tend to be event-driven and volatile, with returns heavily influenced by clinical trial outcomes, regulatory approvals, patent protection, and drug pricing and reimbursement policies.
• Eli Lilly is highlighted for its diabetes and obesity portfolio (e.g., Mounjaro, Trulicity, Zepbound), KalVista is a clinical‑stage developer of Sebetralstat for hereditary angioedema, and Teva is noted for its broad generics and specialty medicines.

Eli Lilly and Company, KalVista Pharmaceuticals, AbbVie, Regeneron Pharmaceuticals, and Teva Pharmaceutical Industries are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription and over-the-counter medications and therapies. For investors, their returns are often driven by clinical trial outcomes, regulatory approvals, patent protection, drug pricing and reimbursement policies, and can be more event-driven and volatile than broader-market equities. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Read Our Latest Research Report on KALV

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read Our Latest Research Report on REGN

Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Read Our Latest Research Report on TEVA

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.